Pharmaceutical composition and use thereof
Patent Information
- Application Number
- MYPI2025003902
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-21
- Filing Date
- 2023-12-27
- Publication Date
- 2024-06-28
AI Technical Summary
Although toripalimab has achieved good results in the treatment of certain malignant tumors, its efficacy still needs to be further improved, especially in some types of tumors such as colon cancer, lung cancer, cervical cancer, head and neck cancer, and nasopharyngeal cancer. and urothelial carcinoma.
A drug combination is provided, which includes Compound I and toripalimab, which can be administered simultaneously or separately, and the administration route, frequency and dosage can be adjusted to improve the anti-tumor effect. The combination can be delivered orally or by injection, and is preferably used for colon cancer, lung cancer, cervical cancer, head and neck cancer, nasopharyngeal cancer and other types of cancer.
Compared with single drugs, the combination of Compound I and toripalimab shows better anti-tumor effect, significantly inhibits tumor growth and improves therapeutic efficacy, especially for colon cancer, cervical adenocarcinoma, and head and neck squamous cell carcinoma in clinical trials. , non-small cell lung cancer, urothelial cancer and other types of tumors have shown significant tumor suppression and tumor shrinkage effects.
Smart Images

Figure PI2025003902_DRAWING_001
Abstract
Description
Drug combinations and their applications
[0001] This application claims priority to Chinese Patent Application No. 2022117029124 filed on December 28, 2022, and Chinese Patent Application No. 2023104407001 filed on April 21, 2023. This application incorporates the entirety of the aforementioned Chinese patent applications. Technical Field
[0002] The present invention belongs to the field of medicine, and in particular relates to a drug combination and application thereof. Background Art
[0003] Cancer remains a major public health concern worldwide. As our understanding of tumor biology deepens, its biological characteristics are gradually being deciphered, including acquisition of signals that maintain proliferation, escape from the regulation of growth inhibitors, sustained activation of replication checkpoints, reprogramming of cellular metabolism, and activation of invasion and metastasis. By leveraging these biological characteristics, traditional chemotherapy, radiotherapy, and targeted drug therapies have achieved promising clinical results in treating various types of tumors.
[0004] The immune checkpoint programmed death receptor 1 (PD-1) is a transmembrane protein expressed on the surface of T cells; programmed death-ligand 1 (PD-L1) is the ligand molecule for PD-1 expressed on the surfaces of tumor cells, APCs, and T cells. When PD-L1 binds to PD-1, it can reduce T cell responses by inhibiting the downstream signaling pathways of TCR activation. Antibodies targeting these immune checkpoints differ from traditional tumor treatments by enhancing the body's own immune system to kill tumors. Currently, antibodies targeting PD-1 and PD-L1, such as nivolumab, atezolizumab, pembrolizumab, durvalumab, and toripalimab, have achieved good results in immunotherapy for a variety of malignancies.
[0005] Toripalimab, developed by Junshi Biosciences, is the first monoclonal antibody targeting PD-1 approved for marketing in China. It has been approved for multiple indications, including melanoma, nasopharyngeal carcinoma, urothelial carcinoma, and esophageal squamous cell carcinoma. While Toripalimab has demonstrated promising results in the treatment of certain malignancies, its efficacy still needs to be further improved.
[0006] Summary of the Invention
[0007] The present invention aims to provide a drug combination of Compound I and Toripalimab and its application. The drug combination of the present invention exhibits better anti-tumor effect than single drugs.
[0008] In a first aspect, the present invention provides a pharmaceutical combination comprising:
[0009] Substance X, wherein Substance X is Compound 1 or a pharmaceutically acceptable salt thereof; and
[0010] Substance Y, wherein substance Y is toripalimab;
[0011] In the pharmaceutical combination, the substance X and substance Y can be administered simultaneously or separately.
[0012] The "simultaneous administration" is, for example, the simultaneous administration of a "separate pharmaceutical composition comprising substance X" and a "separate pharmaceutical composition comprising substance Y".
[0013] "Separate administration" means, for example, that a "separate pharmaceutical composition containing substance X" and a "separate pharmaceutical composition containing substance Y" are administered separately at different times, for example, one of the "separate pharmaceutical composition containing substance X" and the "separate pharmaceutical composition containing substance Y" is administered first, and the other is administered subsequently. The separate administration may be close in time or remote in time.
[0014] Whether administered simultaneously or separately, the administration regimens of component X and component Y (including administration route, administration frequency, administration dosage, administration interval, etc.) may be the same or different, and may be adjusted as needed by those skilled in the art to provide the optimal therapeutic effect.
[0015] In some embodiments, the substance X is administered orally.
[0016] In some embodiments, the substance Y is administered by injection (eg, intravenous, subcutaneous, intraperitoneal, or intramuscular).
[0017] In some embodiments, the substance X is administered orally; and the substance Y is administered by injection (eg, intravenous, subcutaneous, intraperitoneal, or intramuscular).
[0018] In another aspect, the present invention also provides a pharmaceutical combination comprising:
[0019] A first pharmaceutical composition comprising a substance X and a pharmaceutical excipient, wherein the substance X is Compound I or a pharmaceutically acceptable salt thereof; and
[0020] The second pharmaceutical composition comprises substance Y and pharmaceutical excipients, wherein the substance Y is toripalimab.
[0021] The first pharmaceutical composition is a separate pharmaceutical composition; the second pharmaceutical composition is a separate pharmaceutical composition.
[0022] In some embodiments, the first pharmaceutical composition is in the form of an oral dosage form.
[0023] In some embodiments, the second pharmaceutical composition is in the form of an injection (eg, intravenous, subcutaneous, or intramuscular).
[0024] In some embodiments, the first pharmaceutical composition is in the form of an oral dosage form; and the second pharmaceutical composition is in the form of an injectable dosage form.
[0025] In another aspect, the present invention provides a combination kit comprising:
[0026] a first container comprising a first pharmaceutical composition as described above; and,
[0027] A second container comprises a second pharmaceutical composition as described above.
[0028] In another aspect, the present invention provides a use of the drug combination as described herein in the preparation of a drug for treating cancer;
[0029] The cancer is preferably colon cancer, lung cancer, cervical cancer, head and neck cancer, nasopharyngeal cancer or urothelial carcinoma, more preferably colon cancer.
[0030] In another aspect, the present invention provides a use of a substance X in the preparation of a medicament for treating cancer, wherein the substance X is Compound I or a pharmaceutically acceptable salt thereof, wherein the substance X is used in combination with a substance Y, wherein the substance Y is toripalimab, and the cancer is preferably colon cancer, lung cancer, cervical cancer, head and neck cancer, nasopharyngeal carcinoma, or urothelial carcinoma, and more preferably colon cancer;
[0031] When the cancer is lung cancer, the lung cancer is preferably non-small cell lung cancer;
[0032] When the cancer is head and neck cancer, the head and neck cancer is preferably head and neck squamous cell carcinoma;
[0033] When the cancer is cervical cancer, the cervical cancer is preferably cervical adenocarcinoma or cervical squamous cell carcinoma.
[0034] In another aspect, the present invention provides a use of a substance Y in the preparation of a medicament for treating cancer, wherein the substance Y is toripalimab, wherein the substance Y is used in combination with a substance X, wherein the substance X is compound I or a pharmaceutically acceptable salt thereof, and the cancer is preferably colon cancer, lung cancer, cervical cancer, head and neck cancer, nasopharyngeal carcinoma, or urothelial carcinoma, and more preferably colon cancer;
[0035] When the cancer is lung cancer, the lung cancer is preferably non-small cell lung cancer;
[0036] When the cancer is head and neck cancer, the head and neck cancer is preferably head and neck squamous cell carcinoma;
[0037] When the cancer is cervical cancer, the cervical cancer is preferably cervical adenocarcinoma or cervical squamous cell carcinoma.
[0038] In another aspect, the present invention provides a method for treating cancer, comprising administering a therapeutically effective amount of the drug combination described herein to a subject (e.g., a human or a mouse) in need thereof, wherein the cancer is preferably colon cancer, lung cancer, cervical cancer, head and neck cancer, nasopharyngeal cancer, or urothelial cancer, more preferably colon cancer;
[0039] When the cancer is lung cancer, the lung cancer is preferably non-small cell lung cancer;
[0040] When the cancer is head and neck cancer, the head and neck cancer is preferably head and neck squamous cell carcinoma;
[0041] When the cancer is cervical cancer, the cervical cancer is preferably cervical adenocarcinoma or cervical squamous cell carcinoma.
[0042] Administration of Substance X and Substance Y
[0043] In some embodiments, the administration regimens (including administration routes, administration doses, administration intervals, etc.) of substance X and substance Y may be the same or different, and may be adjusted as needed by those skilled in the art to provide optimal therapeutic effects.
[0044] In some embodiments, the substance X and substance Y can be administered simultaneously or separately.
[0045] In some embodiments, the substance X is administered orally.
[0046] In some embodiments, the substance Y is administered by injection (eg, intravenous, subcutaneous, intraperitoneal, or intramuscular).
[0047] In some embodiments, the substance X is administered orally; and the substance Y is administered by injection (eg, intravenous, subcutaneous, intraperitoneal, or intramuscular).
[0048] In some embodiments, the administration frequency of the substance X can be QD (once a day), QOD (every other day) or BID (twice a day), preferably QD.
[0049] In some embodiments, the dosage of the substance X administered each time can be based on the subject's body weight, and a non-limiting example range can be 0.1 mg / kg-1 mg / kg (referring to a single dose), such as 0.2 mg / kg. In some embodiments, the dosage of Compound I is 0.2 mg / kg.
[0050] In some embodiments, the dosage of substance X administered is 0.1-2.0 mg / time, for example: 0.1 mg / time, 0.2 mg / time, 0.3 mg / time, 0.4 mg / time, 0.5 mg / time, 0.6 mg / time, 0.7 mg / time, 0.8 mg / time, 0.9 mg / time, 1.0 mg / time, 1.1 mg / time, 1.2 mg / time, 1.3 mg / time, 1.4 mg / time, 1.5 mg / time, 1.6 mg / time, 1.7 mg / time, 1.8 mg / time, 1.9 mg / time or 2.0 mg / time, preferably 1.1 mg / time.
[0051] In some embodiments, the substance X is orally administered at the above-mentioned dosage and frequency; for example, the substance X is orally administered at 0.2 mg / kg, QD. In some embodiments, the substance X is orally administered at 1.1 mg / time, QD.
[0052] The substance Y can be administered according to the subject's body weight, and a non-limiting example range can be 0.1-10 mg / kg (referring to a single dose), preferably 1-5 mg / kg, such as 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg or 5 mg / kg; in some embodiments, the dose of toripalimab is 1 mg / kg.
[0053] In some embodiments, the dosage of substance Y is 6-600 mg / time, for example: 40 mg / time, 80 mg / time, 120 mg / time, 160 mg / time, 200 mg / time, 240 mg / time, 280 mg / time, 320 mg / time, 360 mg / time, 400 mg / time, 440 mg / time, 480 mg / time, 520 mg / time, 560 mg / time or 600 mg / time, preferably 240 mg / time.
[0054] The frequency of administration of the substance Y may be QW (once a week), BIW (twice a week), Q2W (once every two weeks), or Q3W (once every three weeks).
[0055] In some embodiments, the substance Y is administered at a frequency of BIW.
[0056] In some embodiments, the substance Y is administered by injection at the above-mentioned dose and frequency; for example, the substance Y is administered by injection at 1 mg / kg, BIW. In some embodiments, the substance Y is administered by injection at 240 mg / time, Q3W.
[0057] When substance X and substance Y are administered separately, they can be administered continuously according to their respective dosing cycles. The dosing cycles of substance X and substance Y can begin at the same time or at different times. For example, substance X and substance Y can be administered continuously according to their respective dosing cycles starting on the same day; alternatively, substance X can be administered two, three, or more days after the start of substance Y administration, and then both can be administered continuously according to their respective dosing cycles.
[0058] As used herein, the term "treat" refers to therapeutic treatment. With respect to a specific condition, treatment means: (1) alleviating the disease or one or more biological manifestations of the condition, (2) interfering with (a) one or more points in the biological cascade that leads to or causes the condition or (b) one or more biological manifestations of the condition, (3) ameliorating one or more symptoms, effects, or side effects associated with the condition or one or more symptoms, effects, or side effects associated with the condition or its treatment, or (4) slowing the progression of the condition or one or more biological manifestations of the condition.
[0059] As used herein, the term "therapeutically effective amount" refers to an amount of a compound that, when administered to a subject, is sufficient to effectively treat a disease or condition described herein. The amount of compound that constitutes a "therapeutically effective amount" will vary depending on the compound, the condition and its severity, and the age of the subject to be treated, but can be adjusted as needed by one skilled in the art.
[0060] As used herein, the term "subject" refers to any animal, preferably a mammal, and most preferably a human, that is about to receive or has received a compound or composition according to an embodiment of the present invention. As used herein, the term "mammal" includes any mammal. Examples of mammals include, but are not limited to, cattle, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., with humans being the most preferred.
[0061] As used herein, the term "pharmaceutically acceptable salt" refers to a salt prepared from a compound with a relatively nontoxic, pharmaceutically acceptable acid or base. When the compound contains a relatively acidic functional group, a base addition salt can be obtained by contacting the neutral form of such compound with a sufficient amount of a pharmaceutically acceptable base in neat solution or in a suitable inert solvent.
[0062] As used herein, the term "container" refers to any container and closure suitable for storing, transporting, dispensing, and / or handling pharmaceutical products.
[0063] As used herein, the term "pharmaceutical excipients" refers to excipients and additives used in the production of pharmaceuticals and the preparation of prescriptions. These excipients are all substances contained in pharmaceutical preparations, other than the active ingredient. For a complete list, see the Pharmacopoeia of the People's Republic of China (2020 Edition), Part IV, or the Handbook of Pharmaceutical Excipients (Raymond C Rowe, 2009 Sixth Edition).
[0064] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention.
[0065] The reagents and raw materials used in the present invention are commercially available.
[0066] The positive progress of the present invention is that the present invention provides a drug combination of Compound I and Toripalimab, which exhibits better anti-tumor effect than single drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0067] Figure 1 is the growth curve of mouse tumor volume. DETAILED DESCRIPTION
[0068] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.
[0069] Example 1: Antitumor effect of Compound I combined with Toripalimab in subcutaneous transplanted tumors of mouse colon cancer cells CT26
[0070] 1.1 Experimental conditions
[0071] BALB / c-hPD1 mice, female, 6.9 weeks (age at the time of inoculation), were provided by Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.
[0072] Tepliizumab was provided by Shanghai Junshi Biopharmaceuticals Co., Ltd.
[0073] Compound I:
[0074] 1.2 Experimental model
[0075] BALB / c-hPD1 mice were subcutaneously inoculated with CT26 cells. CT26 cells were provided by Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.
[0076] 1.3 Cell culture
[0077] Mycoplasma testing of CT26 cells was negative, and the recovery passage was Pn+8. Mouse colon cancer CT26 cells were cultured in monolayers in RPMI1640 medium supplemented with 10% (v / v) fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin at 37°C, 5% CO2, and 95% relative humidity. The cells were trypsinized and passaged according to cell density. When the cells were in the logarithmic growth phase, the digested cells were used for inoculation.
[0078] 1.4 Tumor inoculation
[0079] CT26 cells in the logarithmic growth phase (inoculation passage Pn+11) were collected, the culture medium was removed and the cells were washed twice with DPBS before inoculation (cell survival rates before and after tumor loading were 94.31% and 91.43%, respectively). The inoculation volume was 5×10 5 cells / 100μL / mouse.
[0080] 1.5 Grouping
[0081] When the tumor volume reaches 80.15 mm 3 At 4 hr, mice were randomly divided into groups according to the tumor volume according to Table 1. The day of grouping was defined as D0.
[0082] Table 1. Dosage regimen
[0083] Remark:
[0084] 1) The vehicle control group was normal saline.
[0085] 2) a. The solvent used was normal saline.
[0086] 3) b, the solvent used was 1% DMSO + 99% (1% methylcellulose).
[0087] 1.6 Administration
[0088] Dosing began on D0 at a volume of 10 μL / g × mouse body weight (g). The dosing schedule is shown in Table 1. For the combined drug group, each drug was administered alone at the same concentration, but with the drug volume doubled. The dosing order remained consistent for each administration.
[0089] 1.7 Observation
[0090] In the early stages, mice were monitored for tumor growth twice a week and weighed twice a week. Later, as tumors grew more rapidly, the observation frequency was adjusted to three times a week. Tumor growth curves (shown in Figure 1) were obtained and analyzed after 40 days of observation.
[0091] 1.8 Experimental Results
[0092] The tumor growth status obtained after 40 days is shown in Table 2 below.
[0093] Table 2
[0094] Note: “-” means no test data
[0095] According to the statistical analysis of tumor volume data on D22, the Toripalimab group (TGI TV =62.16%, tumor growth inhibition rate = 1-tumor weight of experimental group / tumor weight of control group), compound I group (TGI TV =84.57%), Tepliizumab combined with compound I group (TGI TV =89.55%) showed significant differences in tumor volume compared with the vehicle control group (P<0.05 or P<0.01). According to the statistical analysis of D31 tumor volume data, the combination group of Teplizumab and Compound I (TGI TV =94.63%), compared with the Tepliizumab monotherapy group (TGI TV =24.42%), Compound I monotherapy group (TGI TV =83.37%) showed significant differences in tumor volume (P<0.05). According to the statistical analysis of tumor volume data on day 40, the tumor volume of the Compound I and Toripalimab combination group was significantly different from that of the Compound I monotherapy group (P<0.05).
[0096] In summary, the results of this experiment showed that in the mouse colon cancer cell CT26 subcutaneous transplant tumor model, compared with the normal saline control group, toripalimab alone, compound I alone, and the combination of compound I and toripalimab all showed tumor inhibitory effects; compared with toripalimab alone and compound I alone, the combination of compound I and toripalimab showed better tumor inhibitory effects.
[0097] Example 2 Efficacy data of Compound I combined with Toripalimab in cervical adenocarcinoma in clinical trials.
[0098] Case Data: Subject 1, a 69-year-old female, underwent a pathology report on October 28, 2022, revealing cervical adenocarcinoma. On November 11, 2022, she provided informed consent to participate in a Phase Ib / II clinical trial evaluating the safety, tolerability, and preliminary efficacy of Compound I combined with Toripalimab in advanced solid tumors. Treatment began on November 18, 2022, with a single 0.7 mg tablet of Compound I administered once daily. The 0.7 mg dose consisted of one 0.5 mg tablet of Compound I and two 0.1 mg tablets of Compound I. Toripalimab was administered as a 240 mg intravenous infusion every three weeks. The baseline target lesion was a confluent lymph node adjacent to the left external iliac vessels, measuring 111 mm in longest diameter. The combination of Compound I and Toripalimab demonstrated significant efficacy, with sustained tumor shrinkage, with a maximum reduction of 17.1% for eight cycles (21 days per cycle).
[0099] Example 3 Clinical trial data on the efficacy of Compound I combined with Toripalimab in head and neck squamous cell carcinoma.
[0100] Case Data: Subject 2, a 59-year-old male, underwent a subtotal laryngectomy (supracranial) on October 28, 2020. Postoperative pathology revealed laryngeal cancer. Postoperative radiotherapy was performed from November 30, 2020, to January 21, 2021. An MRI scan revealed recurrence of the cancer on November 15, 2022. Subject 2 provided informed consent on November 17, 2022, to participate in a Phase Ib / II clinical trial evaluating the safety, tolerability, and preliminary efficacy of Compound I in combination with Toripalimab in patients with advanced solid tumors. Treatment began on November 25, 2022, with a single 0.7 mg dose of Compound I tablets administered once daily. The 0.7 mg dose consisted of one 0.5 mg Compound I tablet and two 0.1 mg Compound I tablets. Toripalimab was administered intravenously at a dose of 240 mg every three weeks. The baseline target lesion was the larynx, with a maximum diameter of 34 mm. After the combination of Compound I and Toripalimab, the therapeutic effect was significant, the tumor was reduced to less than 5 mm, showing PR and 85.3% tumor shrinkage. The subject's PR was maintained for more than 10 cycles (each cycle was 21 days).
[0101] Example 4 Efficacy data of Compound I combined with Toripalimab in non-small cell lung cancer in clinical trials.
[0102] Case Data: Subject 3, a 73-year-old male, had non-small cell lung cancer (NSCLC) diagnosed with immunohistochemistry and high PD-L1 expression, while tissue genetic testing revealed EGFR / ALK double negativity. On July 21, 2023, he consented to participate in a Phase Ib / II clinical trial evaluating the safety, tolerability, and preliminary efficacy of Compound I in combination with Toripalimab in patients with advanced solid tumors. He received a single 0.9 mg tablet of Compound I once daily, consisting of one 0.5 mg tablet and four 0.1 mg tablets of Compound I. Toripalimab was administered intravenously at a dose of 240 mg every three weeks. The combination of Compound I and Toripalimab demonstrated significant efficacy, with tumor shrinkage of 48.2%, a partial response (PR) (≥30% reduction in the sum of the largest diameters of target lesions, maintained for at least four weeks).
[0103] Example 5 Efficacy data of Compound I combined with Toripalimab in urothelial carcinoma in clinical trials.
[0104] Case Data: Subject 4, a 71-year-old female, had a pathology report in June 2023 showing right ureteral urothelial carcinoma. She had previously experienced relapse and resistance to first-line gemcitabine plus cisplatin. On July 14, 2023, she provided informed consent to participate in a Phase Ib / II clinical trial evaluating the safety, tolerability, and preliminary efficacy of Compound I combined with Toripalimab in advanced solid tumors. Treatment began on July 17, 2022, with a single 1.1 mg tablet of Compound I administered once daily (two 0.5 mg Compound I tablets and one 0.1 mg Compound I tablet). Toripalimab was administered intravenously at a dose of 240 mg every three weeks. The baseline target lesion was located on the left bladder wall and right arm, totaling 81.8 mm. After the combination of compound I and toripalimab, the therapeutic effect was significant, with continuous tumor shrinkage, the maximum tumor shrinkage to 38.9 mm, a tumor reduction of 52.4%, and PR lasting for at least 6 cycles (each cycle was 21 days).
[0105] Example 6 Efficacy data of Compound I combined with Toripalimab in nasopharyngeal carcinoma in clinical trials.
[0106] Case Data: Subject 5, a 54-year-old male, had a pathology report showing nasopharyngeal carcinoma. He relapsed after undergoing radical radiotherapy in July-August 2022. On February 13, 2023, he provided informed consent to participate in a Phase Ib / II clinical trial evaluating the safety, tolerability, and preliminary efficacy of Compound I combined with Toripalimab in patients with advanced solid tumors. Treatment began on February 24, 2023, with a single 0.9 mg dose of Compound I tablets administered once daily. The 0.9 mg dose consisted of one 0.5 mg Compound I tablet and four 0.1 mg Compound I tablets. Toripalimab was administered intravenously at a dose of 240 mg every three weeks. Baseline target lesions were a 26 mm portal venous phase 17-thick lymph node (left axilla) and an 18 mm portal venous phase 19-thick lymph node, totaling 44 mm. After the combination of compound I and toripalimab, the therapeutic effect was significant, and the tumor reached PR (partial remission, the sum of the maximum diameters of target lesions decreased by ≥30%, maintained for at least 4 weeks) and was maintained for more than 12 cycles (21 days per cycle). The tumor continued to shrink during the treatment, with the maximum tumor shrinkage rate being 72.7%.
[0107] Example 7 Efficacy data of Compound I combined with Toripalimab in cervical squamous cell carcinoma in clinical trials.
[0108] Case Information: Subject 6, a 59-year-old female, was initially diagnosed with cervical squamous cell carcinoma in March 2020 and received concurrent chemoradiotherapy. Following disease progression, she provided informed consent on March 31, 2023, to participate in a Phase Ib / II clinical trial evaluating the safety, tolerability, and preliminary efficacy of Compound I in combination with Toripalimab in patients with advanced solid tumors. Treatment began on April 7, 2023, with a single 1.1 mg dose of Compound I tablets administered once daily (two 0.5 mg Compound I tablets and one 0.1 mg Compound I tablet). Toripalimab was administered intravenously at a dose of 240 mg every three weeks. The baseline target lesion was a left cervical lymph node with a maximum diameter of 15 mm. The combination of Compound I and Toripalimab demonstrated significant efficacy, with sustained tumor reduction, reaching a maximum of 10 mm, with a 36.3% response rate (PR), which was sustained for eight cycles (21 days per cycle).
[0109] Example 8 Efficacy data of Compound I combined with Toripalimab in cervical squamous cell carcinoma in clinical trials.
[0110] Case Data: Subject 7, a 75-year-old female, received a pathology report on March 31, 2023, revealing invasive squamous cell carcinoma of the cervix. On April 4, 2023, she provided informed consent to participate in a Phase Ib / II clinical trial evaluating the safety, tolerability, and preliminary efficacy of Compound I in combination with Toripalimab in patients with advanced solid tumors. Treatment began on April 7, 2023, with a single 1.1 mg dose of Compound I tablets administered once daily (two 0.5 mg Compound I tablets and one 0.1 mg Compound I tablet). Toripalimab was administered intravenously at a dose of 240 mg every three weeks. The baseline target lesion was located in the cervix, with a maximum diameter of 21 mm. The combination of Compound I and Toripalimab demonstrated significant efficacy, with sustained tumor reduction, reaching a maximum reduction of 5 mm (PR), with a tumor reduction rate of 76.2%, and sustained for at least 10 cycles (21 days per cycle).
[0111] Example 9 Clinical trial data on the efficacy of Compound I combined with Toripalimab in cervical squamous cell carcinoma.
[0112] Case Information: Subject 8, a 48-year-old female, had a pathology report on February 8, 2022, showing keratinizing invasive squamous cell carcinoma of the cervix. She had previously experienced relapse and resistance to first-line paclitaxel plus cisplatin. On June 2, 2023, she provided informed consent to participate in a Phase Ib / II clinical trial evaluating the safety, tolerability, and preliminary efficacy of Compound I combined with Toripalimab in advanced solid tumors. Treatment began on June 9, 2023, with a single 1.1 mg tablet of Compound I administered once daily (two 0.5 mg Compound I tablets and one 0.1 mg Compound I tablet). Toripalimab was administered intravenously at a dose of 240 mg every three weeks. The baseline target lesion was in the vaginal area, with a maximum diameter of 36 mm. After the combination of compound I and toripalimab, the therapeutic effect was significant and the tumor was continuously shrunk. The maximum tumor shrinkage ratio was 36.1% (23mm, PR) and lasted for at least 8 cycles (21 days per cycle).
[0113] Example 10 Efficacy data of Compound I combined with Toripalimab in head and neck squamous cell carcinoma in clinical trials.
[0114] Case Data: Subject 9, a 73-year-old male, was initially diagnosed with right maxillary gingival squamous cell carcinoma in August 2021. That same month, he underwent extended right maxillary resection, extended local resection of the right palatal tumor, and right cervical lymph node dissection. He had previously experienced first-line treatment with carrelizumab and SI-B001 (an EGFR / HER3 dual-antibody) combined with paclitaxel, which resulted in drug resistance and relapse. On June 27, 2023, he consented to participate in a Phase Ib / II clinical trial evaluating the safety, tolerability, and preliminary efficacy of Compound I combined with toripalimab in advanced solid tumors. Treatment began on July 2, 2023, with a single dose of Compound I tablets (1.1 mg) administered once daily, consisting of two 0.5 mg Compound I tablets and one 0.1 mg Compound I tablet. Toripalimab was administered as an intravenous infusion of 240 mg every three weeks. The baseline target lesion was on the right cheek, with a maximum diameter of 30 mm. The combination of Compound I and Toripalimab demonstrated significant efficacy, with sustained tumor shrinkage, with a maximum tumor shrinkage rate of 100% (CR, complete remission) and lasting for at least 6 cycles (21 days per cycle).
[0115] Although the above describes specific embodiments of the present invention, it should be understood by those skilled in the art that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.
Claims
1. A pharmaceutical combination comprising: Substance X, wherein substance X is Compound I or a pharmaceutically acceptable salt thereof; and, Substance Y, wherein the substance Y is toripalimab; 2. The pharmaceutical combination according to claim 1, characterized in that It meets one or more of the following conditions: (1) Substance X and substance Y are administered simultaneously or separately; (2) the substance X is administered orally; (3) The substance Y is administered by injection.
3. A pharmaceutical combination comprising: A first pharmaceutical composition comprising a substance X and a pharmaceutical excipient, wherein the substance X is Compound I or a pharmaceutically acceptable salt thereof; and, A second pharmaceutical composition, comprising a substance Y and a pharmaceutical excipient, wherein the substance Y is toripalimab; 4. The pharmaceutical combination according to claim 3, characterized in that It meets one or more of the following conditions: (1) The first pharmaceutical composition is presented in an oral dosage form; (2) The second pharmaceutical composition is presented in the form of an injection.
5. A combination kit comprising: A first container comprising a first pharmaceutical composition as claimed in claim 3 or 4; and, A second container comprising the second pharmaceutical composition according to claim 3 or 4.
6. Use of the drug combination according to any one of claims 1 to 4 in the preparation of a drug for treating cancer.
7. Use of a substance X in the preparation of a drug for treating cancer, wherein the substance X is compound I or a pharmaceutically acceptable salt thereof, characterized in that: The substance X is used in combination with substance Y, and the substance Y is Teplizumab; 8. Use of a substance Y in the preparation of a drug for treating cancer, wherein the substance Y is Teplizumab, characterized in that: The substance Y is used in combination with a substance X, wherein the substance X is compound I or a pharmaceutically acceptable salt thereof; 9. The use according to any one of claims 6 to 8, characterized in that: The cancer is colon cancer, lung cancer, cervical cancer, head and neck cancer, nasopharyngeal cancer or urothelial cancer, preferably colon cancer; When the cancer is lung cancer, the lung cancer is preferably non-small cell lung cancer; When the cancer is head and neck cancer, the head and neck cancer is preferably head and neck squamous cell carcinoma; When the cancer is cervical cancer, the cervical cancer is preferably cervical adenocarcinoma or cervical squamous cell carcinoma.
10. The use according to any one of claims 6 to 9, characterized in that: It meets one or more of the following conditions: (1) The substance X and substance Y may be administered simultaneously or separately; (2) the substance X is administered orally; (3) the substance Y is administered by injection; (4) The substance X is administered according to the subject's body weight, with an administration dose of 0.1 mg / kg-1 mg / kg, for example 0.2 mg / kg; (5) The dosage of the substance X is 0.1-2.0 mg / time, for example, 0.1 mg / time, 0.2 mg / time, 0.3 mg / time, 0.4 mg / time, 0.5 mg / time, 0.6 mg / time, 0.7 mg / time, 0.8 mg / time, 0.9 mg / time, 1.0 mg / time, 1.1 mg / time, 1.2 mg / time, 1.3 mg / time, 1.4 mg / time, 1.5 mg / time, 1.6 mg / time, 1.7 mg / time, 1.8 mg / time, 1.9 mg / time or 2.0 mg / time, preferably 1.1 mg / time; (6) The frequency of administration of the substance X is QD, QOD or BID, for example, QD; (7) The substance Y can be administered according to the subject's body weight at a dosage of 0.1-10 mg / kg, such as 1-5 mg / kg, such as 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg or 5 mg / kg; (8) The dosage of substance Y is 6-600 mg / time, for example, 40 mg / time, 80 mg / time, 120 mg / time, 160 mg / time, 200 mg / time, 240 mg / time, 280 mg / time, 320 mg / time, 360 mg / time, 400 mg / time, 440 mg / time, 480 mg / time, 520 mg / time, 560 mg / time or 600 mg / time, preferably 240 mg / time; (9) The frequency of administration of the substance Y is QW, BIW, Q2W or Q3W, for example, Q2W or Q3W.
